-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $130

Benzinga·04/29/2026 12:53:49
Listen to the news
Stifel analyst James Condulis maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $125 to $130.